Despite being a major contributor to the economy, the pharmaceutical industry in Scotland...
- A heath check for Scotland’s pharmaceutical industry
- Pharma Technology Focus: Scottish pharma gets a health check
- MHRA recalls a further three batches of sartan-based products
- No-deal Brexit could put UK patients at risk of fake medicines
- FDA returns to work post-shutdown, but February funding lapse looms
A heath check for Scotland’s pharmaceutical industry
Despite being a major contributor to the economy, the pharmaceutical industry in Scotland has experienced a decline since 2012 when R&D spending and employment began to drop. But, as new figures suggest the beginning of a turnaround, is there cause to be optimistic for the industry’s future?
Pharma Technology Focus: Scottish pharma gets a health check
In this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced from corn, using machine learning to accelerate diagnosis and treatment of rare diseases, and much more.
MHRA recalls a further three batches of sartan-based products
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has announced it has recalled three more batches of irbesartan as part of its continued investigation into potential N-nitrosodiethylamine (NDEA) contamination of sartan-containing medicines, which are indicated for high blood pressure and heart attacks.
Pharmaceutical packaging in 2019: the view from Origin’s Rich Quelch
The pharmaceutical packaging market is always challenging and 2019 will be no exception. What will rising demand from emerging economies, ageing demographics, new technologies and drug discoveries mean for pharmaceutical packaging in 2019? Rich Quelch, Global Head of Marketing, Origin gives his predictions.
No-deal Brexit could put UK patients at risk of fake medicines
The Association of the British Pharmaceutical Industry (ABPI), a trade group representing drugmakers in the UK, has warned that patients in the country could be at risk of fake medicines in the event of a no-deal Brexit.
FDA returns to work post-shutdown, but February funding lapse looms
President Donald Trump stated the chances of reaching a deal before the next funding lapse are “less than 50–50” and another shutdown is “certainly an option”.
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Reimbursement setback for first-in-class drug Aimovig
The migraine market had a landmark year in 2018, seeing the launch of three calcitonin gene-related peptide (CGRP) antagonists, a highly anticipated new class of drugs given these are specifically approved for migraine prevention.
Does switching biologics impact sales in the psoriasis market?
GlobalData believes that in addition to impacting the treatment outcomes for patients, switching biologics also has a significant commercial impact on the sales of less efficacious biologics in the psoriasis market.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.